Trial Profile
A Randomized Phase III Trial on the Effect of Elotuzumab in VRD Induction /Consolidation and Lenalidomide Maintenance in Patients With Newly Diagnosed Myeloma
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 22 Jan 2024
Price :
$35
*
At a glance
- Drugs Elotuzumab (Primary) ; Lenalidomide (Primary) ; Bortezomib; Dexamethasone
- Indications Multiple myeloma
- Focus Therapeutic Use
- Acronyms GMMG-HD6
- 12 Dec 2023 Results presented at the 65th American Society of Hematology Annual Meeting and Exposition
- 12 Nov 2023 Results (n=179) assessing the effects of prolonged lenalidomide induction and isatuximab- or elotuzumab-containing quadruplet induction therapies on PBSC mobilization and collection from GMMG-HD6 (NCT02495922) and GMMG-HD7 (NCT03617731) trials, published in the BMC Cancer.
- 14 Dec 2021 Results of Intergroup Analysis from phase III trials, HD4, MM5 and HD6 and European Myeloma Network (EMN) 02/ Dutch-Belgian Cooperative Trial Group for Hematology Oncology Foundation (HOVON) 95 presented at the 63rd American Society of Hematology Annual Meeting and Exposition